Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
| dc.creator | Rha, SY; Wyrwicz, LS; Weber, PEY; Bai, Y; Ryu, MH; Lee, J; Rivera, F; Alves, GV; Garrido, M; Shiu, KK; Fernandez, MG; Li, J; Lowery, M; Cil, T; Cruz, FJSM; Qin, S; Yin, L; Bordia, S; Bhagia, P; Oh, DY | |
| dc.date | 2023 | |
| dc.date.accessioned | 2023-07-17T14:53:54Z | |
| dc.date.available | 2023-07-17T14:53:54Z | |
| dc.identifier | 10.1016/j.annonc.2023.01.006 | |
| dc.identifier | http://repositorioufro.cl/s/repositorio-ufro/item/58 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/7498213 | |
| dc.format | ||
| dc.source | ANNALS OF ONCOLOGY | |
| dc.title | Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study | |
| dc.type | Artículo de revista |